13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.

@article{Silfverdal201313ValentPC,
  title={13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.},
  author={Sven Arne Silfverdal and C O Flodmark and Lars Rombo and Susan P Tansey and Mohinder Kaur Sidhu and James Trammel and Emilio A. Emini and William C. Gruber and Daniel J Scott and Alejandra C Gurtman},
  journal={Vaccine},
  year={2013},
  volume={31 9},
  pages={1284-92}
}
BACKGROUND As 13-valent pneumococcal conjugate vaccine (PCV13) is introduced, children who began vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) may complete their vaccination with PCV13. This open-label phase 3 study evaluated immunogenicity and safety of PCV13 in Swedish infants and toddlers previously given 1 or 2 doses of PCV7 during infancy. METHODS Healthy infants previously given PCV7 at ages 3 months (group 1; n=118) or 3 and 5 months (group 2; n=116) received PCV13 at… CONTINUE READING